{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":6,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03715478\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-16T20:50:44.480Z","note":"Automated from all 21 indexed sources (Sep 2022 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":21,"text":"- Whether less frequent belantamab dosing keeps response depth while reducing ocular events\n- Whether single-arm results reflect patient selection rather than benefit over a historical control\n- Whether prior anti-CD38 refractoriness or triple-class refractory status changes benefit from belantamab-pomalidomide-dexamethasone\n- Whether γδ T-cell expansion and T-cell receptor repertoire can identify who responds to belantamab","kind":"questions"},"drugs_tested":[["belantamab mafodotin","pomalidomide","dexamethasone"]],"indication":"relapsed and/or refractory multiple myeloma","name":"ALGONQUIN","nct_id":"NCT03715478","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=algonquin-nct03715478. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.","label":"GSK2857916 with Pomalidomide and Dexamethasone","type":"EXPERIMENTAL"}],"collaborators":["GlaxoSmithKline"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Relapsed and/or Refractory Multiple Myeloma"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"GSK2857916 with Pomalidomide and Dexamethasone","otherNames":["Pomalyst"],"type":"DRUG"}],"last_update":"2026-10-22","lead_sponsor":"Canadian Myeloma Research Group","official_title":"A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"9 months"},{"measure":"Overall Response Rate (ORR)","timeFrame":"60 months"}],"references":[{"citation":"Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Reece D. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4.","pmid":"38177852","type":"DERIVED"}],"start_date":{"date":"2018-11-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","url":"https://clinicaltrials.gov/study/NCT03715478"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/algonquin-nct03715478"}